Adrian L. Harris
Molecular Biology · 2000–2018
A researcher in the Science corpus: 23 papers; trusts 8 researchers and is trusted by 51 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 297 citations into it; #864 of 17,773 by trust here, #1,669 by citations
- Cancer Research — 258 citations into it; #44 of 1,780 by trust here, #80 by citations
- Biotechnology — 8 citations into it
- Neurology — 5 citations into it
Whom Adrian L. Harris trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Adrian L. Harris overall
- Hamish W. King
- J. Mazumdar
- Marloes J. M. Gooden
- Dai Fukumura
- P. Storz
- G. Semenza
- W. Luo
- J. Overgaard
- M. Michael
- V. Reddy Dondeti
Papers from Adrian L. Harris's perspective
Ordered by how strongly the researchers Adrian L. Harris trusts endorse each paper. Same corpus, a different order for every researcher.
- Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. (Genes & Development)
- Targeting HIF-1 for cancer therapy (Nature Reviews. Cancer)
- Hypoxia — a key regulatory factor in tumour growth (Nature Reviews. Cancer)
- Why do cancers have high aerobic glycolysis? (Nature Reviews. Cancer)
- C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. (Cell)
- Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells (Molecular and Cellular Biology)
- Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis (Proceedings of the National Academy of Sciences of the United States of America)
- HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. (Cell Metabolism)
- Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* (Journal of Biological Chemistry)
- Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. (Journal of the National Cancer Institute)
Their papers
- Hypoxia — a key regulatory factor in tumour growth (2002) — 5,276 citations
- Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* (2004) — 1,117 citations
- How cancer metabolism is tuned for proliferation and vulnerable to disruption (2012) — 878 citations
- Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization (2011) — 626 citations
- Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress (2015) — 766 citations
- Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma (2008) — 1,768 citations
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study (2003) — 2,085 citations
- Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis (2011) — 1,325 citations
- hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer (2008) — 642 citations
- Antiangiogenic therapy in oncology: current status and future directions. (2016) — 736 citations
- Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. (2014) — 610 citations
- Consensus guidelines for the use and interpretation of angiogenesis assays (2018) — 555 citations
- Advances in Hypoxia-Inducible Factor Biology. (2017) — 752 citations
- Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. (2007) — 829 citations
- Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) — 1,014 citations
- Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. (2006) — 1,192 citations
- Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) — 1,237 citations
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. (2005) — 7,387 citations
- REporting recommendations for tumour MARKer prognostic studies (REMARK) (2005) — 777 citations
- Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma (2005) — 993 citations